Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clopidogrel
Drug ID BADD_D00504
Description Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Indications and Usage Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
Marketing Status approved
ATC Code B01AC04
DrugBank ID DB00758
KEGG ID D07729; D10823; D10824
MeSH ID D000077144
PubChem ID 60606
TTD Drug ID D0N0TZ
NDC Product Code 42543-714; 50090-4918; 52605-083; 16729-218; 0024-1171; 68788-8190; 72578-012; 65977-0037; 52605-082; 63187-362; 63629-4728; 70518-0400; 33342-060; 42543-713; 65162-414; 0093-7314; 16729-219; 61919-007; 67296-1840; 50090-2598; 50090-5781; 0024-1332; 61919-737; 70771-1062; 16714-052; 68071-2813; 68071-4138; 71335-0581
UNII A74586SNO7
Synonyms Clopidogrel | SC 25989C | SC 25990C | SR 25989 | Clopidogrel-Mepha | Clopidogrel Mepha | Clopidogrel Sandoz | Iscover | Clopidogrel Napadisilate | Clopidogrel Hydrochloride | PCR 4099 | PCR-4099 | Clopidogrel Besylate | Clopidogrel Besilate | Clopidogrel, (+)(S)-isomer | Plavix | Clopidogrel Bisulfate
Chemical Information
Molecular Formula C16H16ClNO2S
CAS Registry Number 113665-84-2
SMILES COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haematoma muscle15.05.03.036; 12.01.07.015; 24.07.01.0910.000107%Not Available
Haemoperitoneum24.07.02.065; 07.07.02.007; 12.01.17.0070.000032%Not Available
Haemorrhagic cholecystitis24.07.01.094; 09.03.01.008--Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Hypersensitivity pneumonitis22.01.01.027; 10.01.03.0560.000032%Not Available
Hypertrophy of tongue papillae07.14.01.0180.000043%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000107%Not Available
Inhibitory drug interaction08.06.03.0140.000101%Not Available
Malabsorption from application site12.07.01.072; 08.02.01.0720.000021%Not Available
Mastocytic enterocolitis10.02.01.091; 07.08.03.0240.000021%Not Available
Medical device site haematoma24.07.01.100; 12.02.21.012; 08.07.01.0280.000021%Not Available
Mucosal disorder08.01.06.0290.000021%Not Available
Periorbital swelling23.04.01.025; 10.01.05.025; 06.08.03.0320.000021%Not Available
Potentiating drug interaction08.06.03.0150.000064%Not Available
Reaction to excipient10.01.01.0420.000075%Not Available
Renal hamartoma20.01.04.026; 16.27.01.0110.000021%Not Available
Spinal subarachnoid haemorrhage12.01.13.010; 24.07.04.037; 17.08.01.0760.000032%Not Available
Therapeutic response changed08.06.01.0590.000068%Not Available
Hyperprothrombinaemia01.01.02.025--Not Available
The 27th Page    First    Pre   27    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene